Abstract
A two‐parameter, human behavior Covid‐19 infection growth model predicts total infections between‐4.2% (overprediction) and 4.5% (underprediction) of actual infections from July 27, 2020 to September 30, 2020 for 10 US States (NY, WA, GA, IL, MN, FL, OH, MI, CA, NC). During that time, total Covid‐19 infections for 9 of the 10 modeled US States grew by 60% (MI) to 95% (MN). Only NY limited Covid‐19 infection growth with an 11% increase from July 27 to September 30, 2020.
September is a month with contraposing effects of increased social interaction (eg, physical school openings) and outdoor temperatures decreasing to the 50F (10C) to 70F (21C) range in which outdoor activities and building ventilation are beneficially increased. All State infection predictions except GA, FL and CA predictions through September 30 are bounded by four prediction scenarios (no school with outdoor temperature effect, no school with no outdoor temperature effect, school with temperature effect, school with no temperature effect). GA, FL and CA continued along a path slightly below the linear infection growth boundary separating infection growth and decay, resulting in overprediction of infection growth over the two month simulation period(‐3.1% for GA, ‐1.9% for FL, and ‐4.5% for CA).
Three eastern States (NY, NC, and GA) are most accurately represented by models that assume no significant change in social interactions coupled with minor outdoor temperature effects. Four midwestern States (IL, MI, MN, OH) are most accurately modeled with minor outdoor temperature effects due to a delayed decrease in average outdoor temperatures in the Midwest. The remaining three States (WA, FL, and CA) are also in good agreement with the model but with differing weather condition and social interaction impacts.
Overall, model predictions continue to support the basic premise that human behavior in the US oscillates across a linear infection growth boundary that divides accelerated infection growth and decaying infection transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is unfunded
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval is required for the research.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used for the report is publicly available.